Skip to content
OpenCapital
Get started

Charles River Laboratories CRL Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies

Revvity logo
RevvityRVTY
——
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——
IQVIA logo
IQVIAIQV
——
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
——
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
——
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
——

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-4.6%—
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%—
Debt / equity1×+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's cash provided by (used in) investing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's cash provided by (used in) investing activity, including discontinued operation?
Charles River Laboratories (CRL) reported cash provided by (used in) investing activity, including discontinued operation of -$407.85M in Q1 2026.
How has Charles River Laboratories's cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
Charles River Laboratories's cash provided by (used in) investing activity, including discontinued operation decreased by 796.8% year-over-year, from -$45.48M to -$407.85M.
What is the long-term trend for Charles River Laboratories's cash provided by (used in) investing activity, including discontinued operation?
Over 4 years (2021 to 2025), Charles River Laboratories's cash provided by (used in) investing activity, including discontinued operation has grown at a -38.3% compound annual growth rate (CAGR), from -$1.45B to -$209.32M.
What does cash provided by (used in) investing activity, including discontinued operation mean?
The net amount of cash spent or generated by investment activities.
How do you interpret cash provided by (used in) investing activity, including discontinued operation?
Negative values typically indicate growth-oriented investment, while positive values may indicate asset liquidation or divestment.
How does cash provided by (used in) investing activity, including discontinued operation compare across companies?
A standard, mandatory subtotal in the cash flow statement for all public companies.